Experienced in Small Cell Lung Cancer (SCLC)

Dr. Daniel G. Lorch

Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine
910 Oakfield Dr, Suite 102, 
Brandon, FL 
Experienced in Small Cell Lung Cancer (SCLC)
910 Oakfield Dr, Suite 102, 
Brandon, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Daniel Lorch is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Brandon, Florida. Dr. Lorch is rated as an Experienced provider by MediFind in the treatment of Small Cell Lung Cancer (SCLC). His top areas of expertise are Lung Metastases, Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease (COPD), Bronchiectasis, and Advanced Bronchoscopy.

His clinical research consists of co-authoring 7 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pulmonary Medicine
Intensive Care Medicine
Sleep Medicine
Licenses
Internal Medicine in FL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

910 Oakfield Dr, Suite 102, Brandon, FL 33511

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial
A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drug: SUVN-G3031
Study Phase: Phase 2
A 12-Month, Randomized, Active-controlled, Open-label Study of the Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men (RE-TUne)
A 12-Month, Randomized, Active-controlled, Open-label Study of the Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men (RE-TUne)
Enrollment Status: Completed
Publish Date: June 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With Standard of Care Versus Standard of Care in Subjects Hospitalized With COVID-19
A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With Standard of Care Versus Standard of Care in Subjects Hospitalized With COVID-19
Enrollment Status: Completed
Publish Date: January 18, 2023
Intervention Type: Drug, Other
Study Drug: Abivertinib
Study Phase: Phase 2
Phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Arm Dose Finding Study to Compare Fixed Dose Combinations of AD109 and AD504 to Atomoxetine or Placebo in Obstructive Sleep Apnea
Phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Arm Dose Finding Study to Compare Fixed Dose Combinations of AD109 and AD504 to Atomoxetine or Placebo in Obstructive Sleep Apnea
Enrollment Status: Completed
Publish Date: December 12, 2022
Intervention Type: Drug
Study Drugs: AD109, AD504, Atomoxetine Hydrochloride
Study Phase: Phase 2
A Randomized, Blinded-controlled Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) in Hospitalized Adult Patients With COVID-19
A Randomized, Blinded-controlled Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) in Hospitalized Adult Patients With COVID-19
Enrollment Status: Withdrawn
Publish Date: August 16, 2022
Intervention Type: Drug, Biological
Study Drug: COVI-AMG COVID-19 Vaccine
Study Phase: Phase 2
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Placebo-Controlled, Double-blind, Fixed-Dose, Multiple Cohort, Multiple Crossover, Dose-Finding Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2
A Randomized, Placebo-Controlled, Double-blind, Fixed-Dose, Multiple Cohort, Multiple Crossover, Dose-Finding Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2
Enrollment Status: Completed
Publish Date: January 16, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

7 Total Publications

Respiratory safety of lemborexant in adult and elderly subjects with moderate-to-severe chronic obstructive pulmonary disease.
Respiratory safety of lemborexant in adult and elderly subjects with moderate-to-severe chronic obstructive pulmonary disease.
Journal: Journal of sleep research
Published: May 02, 2024
Similar Doctors
Distinguished in Small Cell Lung Cancer (SCLC)
Dr. Deepak T. Patel
Pulmonary Medicine
Distinguished in Small Cell Lung Cancer (SCLC)
Dr. Deepak T. Patel
Pulmonary Medicine
119 Us Hwy 27 N, 
Sebring, FL 
 (58.9 miles away)
863-382-0009
Languages Spoken:
English, Hindi, Spanish
See accepted insurances
Accepting New Patients

Deepak Patel is a Pulmonary Medicine provider in Sebring, Florida. Dr. Patel is rated as a Distinguished provider by MediFind in the treatment of Small Cell Lung Cancer (SCLC). His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, Tracheobronchopathia Osteoplastica, Advanced Bronchoscopy, and Gastrostomy. Dr. Patel is currently accepting new patients.

Advanced in Small Cell Lung Cancer (SCLC)
Dr. Richard Aranibar
Pulmonary Medicine
Advanced in Small Cell Lung Cancer (SCLC)
Dr. Richard Aranibar
Pulmonary Medicine

Intercoastal Medical Group Inc

11505 Rangeland Pkwy, 
Bradenton, FL 
 (34.9 miles away)
941-907-6016
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Richard Aranibar is a Pulmonary Medicine provider in Bradenton, Florida. Dr. Aranibar is rated as a Distinguished provider by MediFind in the treatment of Small Cell Lung Cancer (SCLC). His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Pleurisy, and Advanced Bronchoscopy. Dr. Aranibar is currently accepting new patients.

Advanced in Small Cell Lung Cancer (SCLC)
Dr. Francis J. Averill
Pulmonary Medicine | Allergy and Immunology
Advanced in Small Cell Lung Cancer (SCLC)
Dr. Francis J. Averill
Pulmonary Medicine | Allergy and Immunology
802 N Belcher Rd, 
Clearwater, FL 
 (27.6 miles away)
727-447-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Francis Averill is a Pulmonary Medicine specialist and an Allergy and Immunologist in Clearwater, Florida. Dr. Averill is rated as a Distinguished provider by MediFind in the treatment of Small Cell Lung Cancer (SCLC). His top areas of expertise are Lung Nodules, Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), and Bronchiectasis. Dr. Averill is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lorch's expertise for a condition
ConditionClose
      View All 37 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile